IP Library Granted Patent US 7,618,987
Granted Patent B2
US 7,618,987 · App. 11/632,000 · Granted Nov 17, 2009

Acylated piperidine derivatives as melanocortin 4-receptor agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,618,987
App. No.
11/632,000
Granted
Nov 17, 2009
Kind
B2
Abstract

Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Claims (67)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 which is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 which is:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

5. The compound of claim 1 wherein the pharmaceutically acceptable salt is the hydrochloride salt.

6. A compound selected from the group consisting of:

r

R10

R5

R7

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

CF 3

1

F

1

F

1

F

1

F

1

Cl

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

1

F

or a pharmaceutically acceptable salt thereof.

Assignments (1)
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023870/0001 →